Four Potential Suitors for Onyx Pharmaceuticals, Inc. (ONXX)

Page 1 of 2

The “people familiar with the matter” are out in full force spouting off about who’s bidding for Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX), reports Reuters and The Wall Street Journal.

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)

The insiders — most likely Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)’s bankers — release the confidential information to help drive up the price. You’ll recall that Amgen, Inc. (NASDAQ:AMGN) recently made an unsolicited bid for $120 per share that Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) rejected before putting itself on the auction block. The more potential bidders, the higher Amgen has to raise its bid, assuming, of course, that Amgen, Inc. (NASDAQ:AMGN) believes what’s reported in the press.

The news flow also encourages shareholders to hold the course; shares currently trade well above the $120 offer. The bidding process will take awhile, and if shares fall, it’s easier for bidders to justify a lower final offer.

Here’s a look at the potential suitors, assuming the bankers are telling the truth, of course.

Obvious
It’s not surprising to see Amgen, Inc. (NASDAQ:AMGN) in the mix of bidders given its initial interest. With its oncology focus, Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) would be a nice fit. At $10 billion, buying Onyx would be the largest purchase Amgen has made since it bought Immunex more than a decade ago. With more than $20 million in the bank, though, Amgen can certainly afford it.

Big pharma
The two big pharma being mentioned by the insiders, Pfizer Inc. (NYSE:PFE) and Bristol Myers Squibb Co. (NYSE:BMY), are the two obvious choices given their focus on oncology.

Bristol Myers Squibb Co. (NYSE:BMY) has build much of its medicine bag and pipeline through acquisitions in a strategy it calls “string of pearls,” so acquiring Onyx would just be adding another pearl — albeit a rather large one. A knock on a big pharma company buying Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) is that it would have to work with Onyx’s partner, Bayer, co-marketing their cancer drug Nexavar, but that shouldn’t phase Bristol Myers Squibb Co. (NYSE:BMY) given that it’s worked with Sanofi SA (ADR) (NYSE:SNY) selling Plavix and more recently hocking diabetes drugs with AstraZeneca plc (ADR) (NYSE:AZN).

Onyx would be an interesting fit with Pfizer. They’re competitors of sorts since Pfizer Inc. (NYSE:PFE)’s Sutent works in basically the same way as Onyx’s Nexavar. But the companies have found separate niches with Sutent getting most of its sales from kidney cancer and Nexavar focused on liver cancer, even though it’s also approved for kidney cancer. Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) and Pfizer Inc. (NYSE:PFE) also have a partnership for another cancer drug in development, palbociclib, so buying Onyx would save Pfizer the having to pay the royalty if the drug is approved.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

Top 6 Cities For The Ultra Rich to Live in Comfort

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!